Chemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Open Access
- 13 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e58466
Abstract
The use of chemotherapy has been proposed to increase the effectiveness of best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC). Previous trials reported inconsistent findings regarding the efficacy and safety of chemotherapy on overall survival (OS) and treatment-related mortality. We performed a systematic review and meta-analysis to evaluate the effects of chemotherapy plus BSC versus BSC alone on survival of patients with NSCLC. We systematically searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials for relevant literature. All eligible studies included patients with NSCLC who had received chemotherapy and BSC or BSC alone. All eligible studies measured at least 1 of the following outcomes: OS or treatment-related mortality. Overall, patients that received chemotherapy plus BSC had significant longer OS than those that received BSC alone (HR, 0.76; 95%CI, 0.69–0.84; P<0.001). Additionally, chemotherapy plus BSC as compared to BSC alone resulted in a 28% RR reduction (95%CI: 12–40; P = 0.001) in 6-month mortality, 11% RR reduction (95%CI: 8–15; P<0.001) in 12-month mortality, and 5% RR reduction (95%CI: 1–8; P = 0.02) in 2-year mortality. Toxicity was greater in patients that received chemotherapy plus BSC. Chemotherapy plus BSC increased the OS and reduced the 6-month, 12-month, and 2-year mortality of NSCLC patients.Keywords
This publication has 33 references indexed in Scilit:
- Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)The Oncologist, 2010
- The Interpretation of Random-Effects Meta-Analysis in Decision ModelsMedical Decision Making, 2005
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Long-term trends in cancer mortality in the United States, 1930-1998Cancer, 2003
- Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trialEuropean Journal of Cancer, 1998
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Cisplatin-Cyclophosphamide-Mitomycin Combination Chemotherapy With Supportive Care Versus Supportive Care Alone for Treatment of Metastatic Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Chemotherapy in non-small cell bronchial carcinoma.Thorax, 1985